Synbiotic as an Adjuvant Therapy for Dyslipidaemia and Gut Health

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 190 participants.

Also called NCT07915687

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 190 participants (planned count) (from the registry)
Sponsor
Universiti Teknologi Mara (from the registry)
Registry
  • NCT NCT07915687
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Malaysia (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07915687. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-02 (anticipated); primary completion 2027-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Synbiotic as an Adjuvant Therapy for Dyslipidaemia and Gut Health
Condition
Dyslipidemia
Intervention (Dietary supplement)
Synbiotic (LAB12 and SWEOAT® Bran)
Intervention (Other)
Oat-based Placebo
Lead sponsor
Universiti Teknologi Mara (class: other)
Collaborator
Dong Foong Manufacturing Sdn. Bhd. (class: not stated)

Record details

Record id
cardio:ct-nct07915687
Content hash
f1438678b55a54aebc4e91e4356ba6d45e170b574f572a8de1c6cbb01010d91b